A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control - the MUSCA study

Trial Profile

A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control - the MUSCA study

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms MUSCA
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
    • 22 May 2017 Accordign to a GlaxoSmithKline media release, post-hoc analysis data presented at American Thoracic Society (ATS) conference 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top